Abstract:Currently the combination of rituximab with chemotherapy is the standard for treating patients with B-cell lymphoma, particularly when high-dose therapy (HDT) plus autotranplant is scheduled, because of the in vivo purge effect of this treatment. However, the effect of rituximab on the harvest of CD34+ cells, on the hematologic recovery after transplant, and on the risk of complication was never really assessed in large series of patients. We retrospectively analyzed our data on 198 patients who were scheduled… Show more
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.